Linnaeus is using its proprietary technology to develop a pipeline of molecules to address the growing problem of microbial infection and drug resistance. Linnaeus also continues to establish partnerships with collaborators for the discovery and development of novel therapeutics.
Our Compounds in Action
New classes of antibiotics that kill Carbapenem Resistant (CRE) Gram negative pathogens are in urgent demand. Using our unique BCP technology we’ve discovered several novel classes of compounds that kill multiple CRE strains including E. coli, A. baumannii, and P. aeruginosa. When left untreated, a multi-drug resistant E. coli strain grows rapidly in time-lapse microscopy (left). When treated with one of our lead compounds, however, this deadly strain rapidly lyses (right).